Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
about
Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitorInterindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidationRoles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Placental transfer of antidepressant medications: implications for postnatal adaptation syndromePharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoringInsights into CYP2B6-mediated drug-drug interactionsGene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomesCytochrome P450-mediated drug metabolism in the brainCYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changesCytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide BioactivationPredictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Bupropion: pharmacology and therapeutic applications.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeAnandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatmentPart 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivoPrevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New GuineaBiomarkers to optimize the treatment of nicotine dependence.Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationThe role of genetic variability in drug metabolism pathways in breast cancer prognosis.Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping indexMulti-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceMethadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Cessation of alcohol consumption decreases rate of nicotine metabolism in male alcohol-dependent smokersNovel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction.Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomesPrevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory.Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic VariationInfluence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymesFrequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
P2860
Q24647242-049DCDE7-FED2-4D05-A58F-69EF67D60D70Q24648578-9994520F-B838-4779-92BC-C02D907D49D4Q25255438-AA6959A3-F684-468D-BCB6-F2287293E976Q26999391-38924C2F-9FB8-4A4A-A066-13BEABEB211AQ27027293-A3051D10-DDDA-41A0-BB8C-3BA59F2C25A7Q28078857-3034A012-2F36-4768-AEB9-AACB82F7FF7FQ28247305-DD4FBD59-0D4C-4BAD-BEF2-92497979F961Q28397217-69C654D6-ECC2-4B91-8FD6-2E4851DDDCA5Q28535164-7CF6F47D-1E1D-4FDF-95DD-06ED449A5B08Q28550763-AF2D21CC-01EF-4110-91FC-3A581CF6A1DEQ33269667-89CF7CE4-5C2D-4358-A78D-9AF44DD013E7Q33451969-3528E78C-9438-4913-A36A-75586C60690BQ33803436-8191F603-38E7-4050-A067-0488611F4835Q34310059-E71591BF-DF01-4043-805A-8D774D03EE98Q34443184-BEFCAD33-20F2-49EB-B131-02EFB3F21FB4Q34569990-DD5FD3C2-379E-4DCB-99C6-0636424188A8Q34824471-A884EBB2-0B4D-4519-9B08-38B07514E9C0Q34856974-71C436E2-6D46-4DD7-B050-9982063885F2Q35059965-EF524F08-31B1-4B12-84A3-0AE7E134ACABQ35584977-6FFF4788-C54F-40F4-9320-DA3ED854A480Q35647150-E33921CE-7D7E-4511-8538-A229000F8CC2Q35669950-E97D6AF5-D2C4-4585-83B2-7CC1B2477FD0Q35773685-785F7895-F5E0-4C36-97AE-2BC89C4D34E6Q35846912-89806FBD-FD89-42AA-A50A-0296B1AA9C18Q36087706-4F085CE8-E0E3-44E4-95D3-518DD4B8EBF3Q36497088-1E226358-B39F-4FD6-8B8E-030D5283CE96Q36562516-82E28707-0207-404D-9A64-F20A77853794Q36631976-59DB025B-0D94-4180-8353-721E76F041ABQ36657589-AFB1041E-3E0B-4F2F-925F-365F40627F42Q36717150-D5BF03F4-6EED-41A1-92D1-0253D74E5DA8Q36885659-8D81A956-B490-4BD6-A880-FB28830388B6Q36936189-8CB79761-F1D8-4BE4-935B-0012B1951A6BQ36951893-2544301E-67FB-44AC-A27A-200E7D83C95AQ37029122-04AD50DE-E2EB-4945-8237-8103426EF864Q37052162-C0EE7CFD-2E1E-4FD0-BE46-03F397E34324Q37062614-48442C74-7891-47A0-A181-273C1FA389E2Q37148882-E9248471-4BFA-4A36-932C-3B12B72BEF0EQ37169244-B619EE2B-50DA-4567-81CB-4B8E4E8F4CE2Q37171678-2F13E4D9-8F02-4C72-A9EC-771ACBEF6CDEQ37186259-0580C0F6-845C-4EA0-B5E8-21F11A773669
P2860
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@ast
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@en
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@nl
type
label
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@ast
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@en
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@nl
prefLabel
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@ast
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@en
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@nl
P2093
P1476
Pharmacogenetic determinants o ...... 2B6 in human liver microsomes.
@en
P2093
David J Greenblatt
Kirk Hogan
Leah M Hesse
Lisa L von Moltke
Michael H Court
Soundararajan Krishnaswamy
P304
P356
10.1097/00008571-200404000-00002
P577
2004-04-01T00:00:00Z